期刊文献+

PD-L1分子在肺癌细胞株上的表达及其生物学意义 被引量:8

The Expression and Biological Significance of PD-L1 on Lung Cancer Cell Lines
下载PDF
导出
摘要 背景与目的目前研究表明,多种人类肿瘤大量表达的PD-L1分子参与了肿瘤免疫逃逸,其机制主要在于肿瘤细胞通过高表达PD-L1分子,与T细胞上的受体PD-1的结合,传递负性调控信号,导致肿瘤抗原特异性T细胞的凋亡和免疫无能。本文着重探讨PD-L1分子在肺癌细胞株上的表达及其对T细胞杀伤效应的调节作用。方法采用常规方法从健康人外周血单个核细胞诱导DCs,并经凋亡肿瘤细胞和激发型CD40单克隆抗体刺激获得成熟DCs,与自体T细胞共育后获得肿瘤特异性CTL细胞;流式细胞术检测肺癌细胞上PD-L1分子的表达;JAM法和单抗阻断实验分析CTL细胞对肺癌细胞株的杀伤效应,ELISA法检测细胞培养上清中IFN-γ的含量。结果经凋亡肿瘤细胞负载的成熟DCs可诱导自体T细胞分化为肿瘤特异性CTL;H1299高表达PD-L1分子(90.3±4.2)%,而A549低表达PD-L1分子(19.4±5.2)%;CTL对A549具有高效特异的杀伤力,而对H1299不能高效杀伤;联合应用PD-L1单抗可促进CTL对H1299的杀伤作用和IFN-γ的分泌(P<0.05)。结论在肺癌细胞株上表达的PD-L1分子,可降低CTL对肺癌细胞的杀伤效应。 Background and objective Tumor-associated PD-L1 expression was recently shown to promote T-cell apoptosis and proposed as a potential mechanism of immune evasion by tumors. On the basis of the ability of tumor-associated PD-L1 to mediate activated T-cell death, it is likely that manipulation of the PD-L1 pathway at defined time points during the development of the T-cell antitumor immune response can enhance the efficacy ofT-cell-based immunotherapy. Here, the levels of expression of PD-L1 on lung cancer cell lines and its role in interaction of CTL and target cells was investigated. Methods Human PBMC derived DCs were loaded with apoptotic tumor cells and stimulated by CD40 mAb (SC 11). Tumor specific CTL was generated in vitro by autologous T cells co-cultured with mature DCs. Expression of PD-L1 on lung cancer cell lines H1299 and A549 were analyzed by FCM. JAM assay was used to detect the cytolytic activity of CTL with or without blocking PD-L1 by PD-L1 mAb respectively.The concentrations of IFN-γ in supernatants from distinct groups were analyzed by ELISA. Results Tumor cells-loaded mature DCs could induce the generation of the tumor specific CTL. Expression of PD-L1 was low on A549 cell, but high on H1299 cell. Blockade of PD-L1 on A549 could not improve cytolytic effect of CTL on target ceUs and IFN-γ production, but fragmentation of H 1299 cells and IFN-γ production were significantly enhanced by the combination of PD-L1 mAb and CTL. Conclusion Expression of PD-L1 on lung cancer cell line can decrease the cytolytic effect of CTL on target cells.
出处 《中国肺癌杂志》 CAS 2009年第8期859-863,共5页 Chinese Journal of Lung Cancer
基金 国家自然科学基金(No.30770947) 江苏省卫生厅项目(No.H200712) 江苏省医学重点人才基金(No.RC2007075)资助~~
关键词 细胞毒T细胞 肺肿瘤 PD-L1 Cytotoxic T-Lymphocytes Lung neoplasms Human PD-L1 protein
  • 相关文献

参考文献19

  • 1Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med, 2003, 81 (5): 281-287.
  • 2Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med, 2002, 8(8): 793-800.
  • 3Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med, 1999, 5(12): 1365-1369.
  • 4Sun J, Xu K, Wu C, et al. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signalingby two functional monoclonal antibodies. Tissue Antigens, 2006, 69(1): 19-27.
  • 5黄建安,杨新静,胡玉敏,穆传勇,张学光.凋亡肿瘤细胞致敏的树突状细胞疫苗治疗肺癌的实验研究[J].肿瘤,2007,27(2):88-91. 被引量:4
  • 6Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death.J Immunol Methods, 1991, 145(1-2): 185-192.
  • 7Ghebeh H, Mohammed S, AI-Omair A, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia, 2006, 8 (3): 190-198.
  • 8Ghebeh H, Tulbah A, Mohammed S, et al. Expression of B7-H 1 in breast cancer patients is strongly associated with high proliferative 10-67 expressing tumor cells. IntJ Cancer, 2007, 121 (4): 751-758.
  • 9Ghebeh H, Barhoush E, Tulbah A, et al. FOXP3+ Tregs and B7-H1^+/PD-1^+ T lymphoeytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer, 2008, 23(8): 57.
  • 10Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infihrating CD8^+ T lymphoeytes are prognostic factors of human ovarian cancer. Proc Natl Aca Sci USA, 2007, 104(9): 3360-3365.

二级参考文献9

  • 1SWISHER S G,ROTH J A.Clinical update of Ad-p53 gene therapy for lung cancer[J].Surg Oncol Clin N Am,2002,11(3):521-535.
  • 2BABATZ J,ROLLIG C,LOBEL B,et al.Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells[J].Cancer Immunol Immunother,2006,55(3):268-276.
  • 3BERARD F,BLANCO P,DAVOUST J,et al.Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells[J].Exp Med,2000,192(11):1535-1544.
  • 4HOLMES L M,LJ J,STRICCA R P,et al.A rapid novel strategy to induce tumor cell-specific cytotoxic T lymphocyte responses using instant dendritomas[J].Immunother,2001,24(2):122-129.
  • 5HIRSCHOWITZ E A,FOODY T,KRYSCIO R,et al.Autologous dendritic cell vaccines for non-small-cell lung cancer[J].Clin Oncol,2004,22(14):2808-2815.
  • 6ZHOU Z H,WANG J F,WANG Y D,et al.An aganist anti-human CD40 monoclonal antibody that induce dendritic cell formation and mature inhibits proliferation of a myeloma cell line[J].Hybridoma,1999,18(6):471-478.
  • 7JEFFORD M,MARASKOVSKY E,CEBON J,et al.The use of dendritic cells in cancer therapy[J].Lancet Oncol,2001(2):343-353.
  • 8YANNELLI J R,STURGILL J,FOODY T,et al.The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC)[J].Lung Cancer,2005,47(3):337-350.
  • 9黄建安,朱一蓓,古涛,席泓,王天立,戴俊,张学光.肺癌患者外周血树突状细胞的生物学特性研究[J].中国肿瘤生物治疗杂志,2003,10(3):175-179. 被引量:4

共引文献3

同被引文献51

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013 [ J]. CA Cancer J Clin, 2013, 63 : 11-30.
  • 2Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer [J]. N Engl J Med, 2002, 346:92-98.
  • 3Marigo I, Dolcetti L, Serafini P, et al. Tumor-induced tolerance and immune suppression by myeloid derived suppressor ceils [ J ]. Immunol Rev, 2008, 222 : 162-179.
  • 4Dang H, Strome SE, Salomao DR, et al. Tumor-associated BT-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion[J]. Nat Med, 2002, 8:793-800.
  • 5Sun J, Xu K, Wu C, et al. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies [ J ]. Tissue Antigens, 2007, 69:19-27.
  • 6Robert C, Sofia JC, Eggermont AM. Drug of the year: programmed death-I receptor/programmed death-1 ligand-1 receptor monoclonal antibodies[J]. EurJ Cancer, 2013, 9:2968- 2971.
  • 7Munir S, Andersen GH, Svane IM, et al. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 + T cells[J]. Oncoimmunology, 2013, 2:e23991.
  • 8Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and Activity of Anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med, 2012, 366:2455-2465.
  • 9Spigel DR, Gettinger SN, Horn L, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [ C ]. ASCO Annual Meeting, Chicago, 2013. United States: American Society of Clinical Oncology: 2013.
  • 10Siegel R,Naishadham D,Jemal A,et al.Cancer statistics,2013[J].CA Cancer J Clin,2013,63(1):11-30.

引证文献8

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部